Slaughter and May has advised Fortescue Zero. Fortescue Zero has announced the acquisition of the Penske Formula E operation, marking a major step in launching its...
Fortescue Zero Acquires Penske Formula E Operation and Launches Formula E Team
Schroders Divests Benchmark to Söderberg & Partners in Strategic Wealth Management Shift
Perella Weinberg Partners and Slaughter and May have advised Schroders. Fenchurch and White & Case have advised Söderberg & Partners. Schroders plc has entered into an...
Videndum Completes £85 Million Oversubscribed Equity Raise
Travers Smith has advised Investec Bank as Sponsor, Global Co-ordinator and Sole Bookrunner. Slaughter and May has advised Videndum Plc. Videndum plc has completed an oversubscribed...
Advent-Led Consortium Agrees £3.8 Billion Acquisition of Spectris
Slaughter and May has advised Spectris; Norton Rose Fulbright has acted for Morgan Stanley & Co. International plc; Ashurst has represented J.P. Morgan Cazenove; Weil has...
Videndum Plc’s £8 Million Cashbox Placing and Revolving Credit Facility
Slaughter and May advised Videndum Plc on the deal. Videndum Plc secured a cashbox placing to raise gross proceeds of c.£8 million and the amendments to...
Montagu Private Equity’s $700 Million Acquisition of Medical Device Components Business From Johnson Matthey Plc
Slaughter and May advised Johnson Matthey Plc (JM) on the sale. Johnson Matthey Plc (JM) completed the sale of its Medical Device Components business (MDC) to...
Swisscom’s €8 Billion Acquisition of Vodafone Italia
Legance, McDermott Will & Emery, White & Case and Travers Smith acted for Swisscom; ADVANT Nctm, Slaughter and May and Linklaters acted for Vodafone. Swisscom, a...
Videndum’s £125 Million Capital Raising
Slaughter and May is advised Videndum plc. on the deal. Videndum plc, a leading global provider of premium branded hardware products and software solutions to the...
AOP Health AG’s Takeover Offer for Shield Therapeutics Plc
Slaughter and May is advising AOP Health International Management AG (AOP) on its mandatory cash takeover offer for Shield Therapeutics plc. Shield Therapeutics, the iron deficiency...